antagonists on renal hemodynamics and glomerular function. glomerular hyperfiltration and renal hypertrophy by blood glucose normalization in diabetic rats. 
Specific intervention studies are a crucial requirement (v) Antisense or ribozyme studies. While the compounds are relatively easy to synthesize, they to demonstrate the pathogenetic relevance of particular molecules and to ultimately develop novel therapeutic unfortunately have to enter the cell in order to act. This renders in vivo studies difficult as the approaches to renal disease. Inhibition studies of cytokines or growth factors provide a good example of the compounds usually have to be transfected in vivo using liposomes or viral vectors. various approaches that have been employed in such studies in vivo.
(vi) Specific interventions with aptamers.
(i) Neutralizing antibodies. Generation of such antibodies is probably the easiest way to accomplish intervention studies. Problems of neutralizing antibodies relate to their immunogenicity in heterolog-What is an aptamer?
ous systems and, more importantly, to non-specific effects of immunoglobulins per se, which may be The term 'aptamer' was originally proposed by difficult to control. Ellington and Szostak based on the latin word aptus, (ii) Natural or designed antagonists (e.g. extracellular i.e. to fit [1] . It describes the property of DNA or domains of receptors or receptor antagonists). An RNA oligonucleotides to specifically bind to other elegant, yet laborious way, which requires the molecules outside or inside of cells. Thus, in this case expression of considerable amounts of recombin-biological effects of the oligonucleotide are not a ant protein. function of the DNA or RNA code (as involved in (iii) Interference with cytokine or growth factor signal-transcription and translation) but rather reside in the ling. An attractive approach since many com-specific three-dimensional structure of the oligonucpounds that inhibit molecules involved in leotide [1, 2] . Aptamers are usually 20-50mers with signalling are simple chemical structures that can distinct structural elements (such as stems, loops, easily be synthesized. A frequent problem of this pseudoknots, helix junctions, G-quartets etc.) that approach, however, is non-specificity of the inter-create a stable framework in which some invariant vention given the convergence of many signalling nucleotides are precisely arranged [3] [4] [5] . It is these pathways and/or toxic in vivo effects. nucleotides at specific positions in the three-(iv) Targeted gene deletion. A laborious way to investi-dimensional structure that are central to the physicogate the function of a mediator, which also suffers chemical interaction of the aptamer with other molecfrom the potential problem that the ontogenetic ules. K d -values for the interaction of aptamers with lack of a single gene might have induced compens-their targets extend from the micromolar to low picomatory mechanisms that blunt the effects of the olar range and are therefore comparable in terms of deficiency.
binding affinity to antibody-antigen interactions [3] [4] [5] . An impressive example of how seemingly minor in Figure 1 , which shows how the exchange of three based libraries) or strand separation (for DNA-based libraries). These amplified sequences are then employed nucleotides in a 42-mer determines whether the aptamer will bind L-citrulline or L-arginine with high for further rounds of the SELEX process, usually 5-12, after which high affinity sequences have been strength [6 ] .
Aptamers have been produced against very diverse sufficiently enriched. These sequences are cloned and can then be evaluated specifically for their binding molecules ranging from organic dyes to nucleotides, such as ATP, to amino acids, peptides and complex properties.
Once a binding sequence has been identified, it can proteins (both extracellular and intracellular) and even disaccharides [3] [4] [5] 7] . be modified further, for example, by testing whether particular substitutions might further increase binding affinity [8] . Other modifications are aimed at improv-
How is an aptamer produced?
ing nuclease resistance, for example by incorporating nucleotides with 2∞-amino-, 2∞-fluoro-or 2∞-O-alkylmoieties instead of natural nucleotides into the In many ways the generation of a particular aptamer sequence [8, 9] . Another interesting approach to resembles evolution in that it starts from a random improving nuclease resistance is the production of mixture of oligonucleotides and then selects for the mirror-image L-oligonucleotides, which are not recog-'best' sequences in a process called systematic evolution nized by natural nucleases [10] . However, for protein of ligands by exponential enrichment (SELEX ) [2, 5] .
targets this requires the prior synthetic preparation of The starting point is the synthesis of single-stranded D-polypeptides. Finally, in order to increase the in vivo nucleic acid libraries (RNA, DNA or modified nucleic residence time of aptamers in plasma (usually they are acids) containing 20-40 randomized positions. This excreted quickly via the kidney because of their small creates an enormous diversity of possible sequences size), their effective molecular size can be increased by (and hence different structures). For example, four anchoring them in liposome bilayers or by coupling different nucleotides at 40 randomized positions will them to inert large molecules such as polyethylene theoretically yield 440 (=1.24×1024) combinations, glycol (PEG) [11] [12] [13] . although in practice starting libraries usually contain no more than about 1015 different sequences. These random sequence regions are flanked by fixed
In vivo applications of aptamers sequences, which are essential for subsequent PCR amplification ( Figure 2 ). This vast array of different sequences is next incubated with a given target molec-There are now several reports on the use of aptamers in vivo. The first, a 15-mer ssDNA antagonist against ule, followed by removal of unbound oligonucleotides. Binding sequences are then amplified by PCR and thrombin was infused into monkeys at doses of up to 0.6 mg/kg/min [14] and led to a two-fold increase in regenerated, either by in vitro transcription (for RNA- 3 . Glomerular immunostaining for type IV collagen in a control rat with anti-Thy 1.1 nephritis on day 9 after disease induction (A) or a rat with anti-Thy 1.1 nephritis, which had received a PDGF-B antagonistic aptamer from day 3 to 8 (B). Note how the marked mesangial expansion and matrix accumulation in the control rat is reduced to almost normal levels in the rat receiving the PDGF-B antagonist. Magnification ×400.
prothrombin time. However, the half-life of the small when given 1-5 min prior to PBMC injection into mice [15] . In vivo activity of aptamers to neutrophil elas-15-mer was in the range of a few minutes. In other experiments a 49-mer L-selectin antagonist, coupled to tase [16 ] erulonephritis model in rats (anti-Thy 1.1 nephritis). We were also able to demonstrate that the PDGF 4. Eaton BE. The joys of in vitro selection: chemically dressing antagonist markedly reduced the mesangial matrix oligonucleotides to satiate protein targets. Curr Opin Chem Biol accumulation ( Fig. 3) . This study not only confirmed Chem Biol 1995; 2: 683-695 In a second in vivo study, again using the anti-Thy The above data provide evidence that specific interven- defined, therapeutic applications of aptamers will con- 273: 20556-20567 stitute the immediate next step. In fact, first therapeutic 18. Floege J, Johnson RJ. Multiple roles for platelet-derived growth interventions using the VEGF antagonist are ongoing factor in renal disease. Miner Electrolyte Metab 1995; 21: 271-282 in patients with age-related macular degeneration.
